Updates in Treatment for Androgenetic Alopecia

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

In this study, injecting foreskin-derived mesenchymal stromal cell exosomes into the scalps of men with androgenetic alopecia significantly increased hair density and patient satisfaction without side effects over a 12-week period.

This study found that treating patients with androgenetic alopecia using exosomes from adipose tissue stem cells over 24 weeks significantly increased hair density and patient satisfaction without severe adverse effects, suggesting a promising alternative treatment for hair loss.

Low-dose oral minoxidil is generally safe for hypertensive patients with hair loss.

IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.

In this study, dutasteride 0.5 mg was found to provide long-term efficacy and safety in treating androgenetic alopecia in Korean men, with 89.9% showing improvement and 93.9% experiencing prevention of disease progression over at least 5 years.

This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study found that while clinical evidence is limited, early preclinical results suggest exosome treatment may enhance hair growth and warrant further research for therapeutic use in alopecia.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This study found that combining botulinum toxin A injections with finasteride and minoxidil increased hair density in patients with androgenic alopecia more effectively than finasteride and minoxidil alone.

This review found that while preclinical studies highlight the potential benefits of exosome therapeutics for hair loss, clinical evidence on their safety and effectiveness for alopecia is currently lacking, requiring further research.

This study found that exosomes derived from bovine colostrum promoted hair growth in mice by activating the Wnt/β-catenin pathway, with effects similar to minoxidil but without adverse effects.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This article describes the characteristics and management of hypertrichosis induced by low-dose oral minoxidil used for hair disorders, but reports no new clinical findings.

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

This study's meta-analysis reported that PRP injections significantly increased hair density compared to baseline and placebo in androgenetic alopecia patients, supporting its use as a beneficial treatment.

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This study found an association between dispensed finasteride and an increased risk of male breast cancer, though uncertainties around confounding factors and potential biases suggest these results should be interpreted with caution.

This study found that women with female pattern hair loss had increased 5α-reductase isozymes and decreased aromatase mRNA levels, potentially affecting their response to treatment.

In this study, platelet-rich plasma injections in mice promoted hair growth and angiogenesis compared to control, as evidenced by longer hair lengths and increased vessel formation.

This review discusses the molecular mechanisms of androgens and androgen receptors in skin disorders, particularly androgenetic alopecia, and reports no new clinical results; it highlights potential areas for future treatment development.

Platelet-Rich Plasma (PRP) is becoming popular for treating hair loss and it's important for dermatologists to understand how it works and its safety.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that low-level laser treatment with the HairMax Lasercomb significantly increased terminal hair density in both men and women with pattern hair loss, with no serious adverse events reported.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.

This study found that interfollicular injection of autologous CD34+ cell-containing PRP preparation improved hair count and thickness in patients with pattern hair loss, with better results than placental extract treatment.

This review discusses the use of electromagnetic radiation, including low-level laser therapy, for hair loss management, but it reports no new clinical results and suggests further research.

This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.

This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.

This study found that autologous platelet-rich plasma increased hair growth potential by enhancing dermal papilla cell proliferation and stimulating key signaling pathways in both cell cultures and mice models.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

Finasteride can cause rare breast growth side effect, with varying recovery after stopping.

This study found that both topical and oral finasteride had similar therapeutic effects in treating male androgenic alopecia, with no significant differences in hair thickness, counts, or bald area size.

This study found that the HairMax LaserComb® significantly increased hair density and was safe and well tolerated for treating androgenetic alopecia in men compared to a sham device.

This study found that 12 months of minoxidil treatment increased hair density and thickness in women with androgenetic alopecia, while alfatradiol primarily stabilized hair loss.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study found that minoxidil stimulates hair follicle growth by promoting dermal papilla cell survival and activating ERK and Akt pathways, which leads to increased proliferation and reduced cell death.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

In this study, the prevalence of androgenetic alopecia among Korean men and women was found to be lower than in caucasians, with Korean men showing more frontal hairline preservation and a higher incidence of 'female pattern' hair thinning.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.